rAd-p53 combined chemotherapy via selective arterial cannula in the treatment of advanced oral cancer, a randomized controlled trial.

Trial Profile

rAd-p53 combined chemotherapy via selective arterial cannula in the treatment of advanced oral cancer, a randomized controlled trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2013

At a glance

  • Drugs Contusugene ladenovec (Primary)
  • Indications Orofacial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 21 May 2012 Actual end date changed from 1 Jun 2007 to 30 Jun 2008 as reported by Chinese Clinical Trial Register.
    • 21 May 2012 Primary endpoint added as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top